The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …

Inflammatory and thrombotic complications and a low loading of dual drugs with different
hydrophilicities remain challenges to treat thrombosis with drug delivery systems (DDSs) …

Rational design of nanomedicine to accelerate thrombolysis and sequentially avoid
thrombolysis-mediated reperfusion injury is still a challenge. Here, we develop a biomimetic …

Intravenous injection of thrombolytic drugs is the most effective strategy for the treatment of
thrombotic diseases. However, the clinical application of most thrombolytic drugs is limited …

Thrombotic occlusions of blood vessels are responsible for life-threatening cardiovascular
disorders such as myocardial infarction, ischemic stroke, and venous thromboembolism …

Thrombolysis is a standard treatment for rapidly restoring blood flow. However, the
application of urokinase-type plasminogen activator (Uk) in clinical therapy is limited due to …

Escape from apoptosis, one of the characteristic features of cancer cells, is a case that
reduces the therapeutic efficacy of apoptosis-inducing molecules used in the cancer …

Natto, a traditional food made of soy-beans fermented with Bacillus subtilis, has been
consumed for over 1000 years, especially in the Eastern Kanto region of Japan. 1-6 It has a …

Lumbrokinase (LK) has strong fibrinolytic and thrombolytic activities, but it has a short half-
life, can be easily inactivated, and may cause hemorrhage as a side effect. This study …

Thrombotic diseases have the characteristics of long latency period, rapid onset, and high
mortality rate, which seriously threaten people's life and health. The aim of this research is to …